Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity
about
Erythropoietin and diabetes mellitusErythropoietin: new directions for the nervous systemCutting through the complexities of mTOR for the treatment of strokeShedding new light on neurodegenerative diseases through the mammalian target of rapamycinIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesFoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis.Oxidative stress: Biomarkers and novel therapeutic pathways.New strategies for Alzheimer's disease and cognitive impairment.Diabetes mellitus: channeling care through cellular discoveryThe "O" class: crafting clinical care with FoxO transcription factors.Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress.Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways.PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotectionNovel avenues of drug discovery and biomarkers for diabetes mellitus.EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes.Age-dependent astroglial vulnerability to hypoxia and glutamate: the role for erythropoietin.Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress.Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.Elevated endogenous erythropoietin concentrations are associated with increased risk of brain damage in extremely preterm neonatesSystemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegenerationTranslating cell survival and cell longevity into treatment strategies with SIRT1Targeting cardiovascular disease with novel SIRT1 pathways.Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xLSIRT1: new avenues of discovery for disorders of oxidative stressCellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways.Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL.Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrityWISP1 (CCN4) autoregulates its expression and nuclear trafficking of β-catenin during oxidant stress with limited effects upon neuronal autophagy.Attempted cell cycle induction in post-mitotic neurons occurs in early and late apoptotic programs through Rb, E2F1, and caspase 3Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB.The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection.Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress.Regeneration in the nervous system with erythropoietinWnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern β-amyloid apoptotic injury of microglia.Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia.Raves and risks for erythropoietinTriple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.The Wnt signaling pathway: aging gracefully as a protectionist?Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies
P2860
Q26777878-E082CBC4-FEB4-47C6-9285-73BCB5E10131Q26828425-9B5ED24D-826D-464B-AD6E-0566FCD33D57Q26851291-1599AE8F-99E1-4E9B-BABD-99A43F047433Q27015640-DB8E1AF5-70C5-408D-B50B-50A9CD3D06BBQ28388335-AC24B6C0-0613-4516-9197-CF8EB3B2507BQ33604706-12A21692-CC82-410B-8E50-850E31E6C180Q33682262-D6846C28-B2F5-463C-88A5-5D499F9CAF5BQ33717008-417E75EE-87A1-4FC8-A40F-F2CB4DC3935FQ33749358-E6E2EE77-75B4-4CAB-8E5E-83F9A03B8228Q33824809-FF4205BA-0426-4837-89BC-DC865C1C9BFBQ33945459-3FF5BFF7-D977-449E-B2DB-464E4A647B77Q34185844-CE10A054-2D70-47B2-831B-108F35BD2053Q34429082-72D42F29-FC43-4B82-96D3-EF34374D0B66Q34552287-C6A55552-D1F3-4683-A756-46C65C44B2F3Q34887803-C8196280-8E24-4819-9575-879F370ED5DFQ35017110-14E446C0-C61A-4AB4-A3A2-3B8A501CAA01Q35146283-B2AE0984-89A7-41BC-81F9-0B456E324A91Q35157985-1D990C21-BDD4-4594-B14E-EBD30B1996D4Q35202607-003AD037-8320-4859-8416-570823762150Q35205276-A62844FB-06AE-4BB2-AA29-5059AD80DB90Q35660308-00D18220-0D95-4FB4-9A9A-3253339C29CCQ35661632-660293AA-3FD7-4075-98BF-8DBDE3C4216EQ35663684-EF7B35CF-F90D-4B0B-B033-9E30FEA1CDA5Q35742785-0CB6CF5A-855A-4233-A70B-7F4BE2217A20Q35757288-2E614807-0D33-47B5-A261-C6662DE8C104Q35879541-F23A2A92-D68D-4207-B048-AA69F52AEA90Q35947388-E2192FE0-C7D2-43CB-B66B-C60A4D2FD5F3Q35950357-89F45956-61AF-4A4E-A18B-7A7145FC4AE2Q35965763-60F944E7-23D1-4FAB-A38C-64FA67B55800Q36002822-1949DA34-40F2-4B5F-81EA-BD21CF2EF03AQ36002858-248BFCDA-CCFF-42C7-9002-D622AF75577CQ36002875-5E789D59-FC8F-4F10-B34B-2A1B4EBD3BE8Q36088734-A905EA85-8144-43CA-AE54-5B0230E9B5F1Q36247651-706D0555-8920-456C-8E6D-CF595B687E14Q36465550-54BF5C34-C1BF-4A7B-B552-865FE153553BQ36597635-8B236407-4FF7-4655-8E38-1A57743A2B72Q36664578-758977F7-8BE0-4E0F-84BE-9F1644AB14D2Q36727444-2090CC3D-38C9-40FE-9495-99BDBDC1CF8AQ36728844-ACA3D77A-1360-4EF8-A3E7-9481015D1D45Q36740470-5DC172B2-E123-4CF0-A9BD-1E0BFC0335C3
P2860
Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Erythropoietin requires NF-kap ...... y during beta-amyloid toxicity
@ast
Erythropoietin requires NF-kap ...... y during beta-amyloid toxicity
@en
type
label
Erythropoietin requires NF-kap ...... y during beta-amyloid toxicity
@ast
Erythropoietin requires NF-kap ...... y during beta-amyloid toxicity
@en
prefLabel
Erythropoietin requires NF-kap ...... y during beta-amyloid toxicity
@ast
Erythropoietin requires NF-kap ...... y during beta-amyloid toxicity
@en
P2093
P2860
P1476
Erythropoietin requires NF-kap ...... y during beta-amyloid toxicity
@en
P2093
Kenneth Maiese
Zhao Zhong Chong
P2860
P304
P356
10.2174/156720205774962683
P577
2005-12-01T00:00:00Z